Background
In hepatocellular carcinoma (HCC), myeloid-derived suppressor cells (MDSCs) play a vital role in the tumor immune microenvironment, significantly impacting tumor initiation and progression. The study of genes linked to MDSCs in predicting the progression of HCC is of significant scholarly significance.
Method
Acquiring a comprehensive single cell RNA sequencing (scRNA-seq) dataset from GEO to extract valuable information and detect distinct cell subgroups through the application of clustering and dimensionality reduction techniques. Moreover, the determination of molecular subtypes that demonstrate excellent clustering performance is achieved by calculating the cumulative distribution function (CDF). The analysis of the immune landscape and tumor immune escape state is conducted in this study using estimation methods, particularly the cibersort algorithm, in conjunction with publicly accessible tools for tumor immune dysfunction and exclusion (TIDE). Furthermore, a Cox regression analysis is employed to establish a gene risk model associated with MDSCs, which is later confirmed using various datasets and dimensions. Moreover, a functional enrichment analysis is performed to detect potential signaling pathways linked to marker genes of MDSCs.
Result
From the scRNA-seq dataset (GSE202642), a collection of 30 subpopulations and 65 marker genes associated with MDSCs were discovered. When clustering the molecular subtypes using marker genes related to MDSCs, there were notable differences in prognostic survival and immune signatures observed between the two subtypes. As a result, an independent prognostic factor for patients with HCC was discovered, which is a 7-gene predictive signature consisting of DAB2, FTL, CSTB, APOE, PLA2G7, PPT1, and ANXA2. Individuals with a lower RiskScore exhibited a reduced survival rate and higher immune infiltration in contrast to patients who had a higher RiskScore.
Conclusion
In summary, a highly effective MDSCs-related marker was created to predict the prognosis and response to immunotherapy in individuals diagnosed with HCC.